Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinical diagnosis of Rheumatoid Arthritis
Disease Activity Score (DAS)28-C-Reactive Protein (CRP) score ≥ 3.2 and ≤5.1
On background methotrexate at least 3 months (≥10mg weekly)
Must be able to self injection or allow a care giver to do it for them
Discontinue all Biologics and Disease-Modifying Anti-rheumatic Drugs (DMARDs) except for methotrexate
You may not be if
Participants who had prior exposure to abatacept or CTLA-4 Ig
Received treatment with rituximab.
Participants who have received treatment with leflunomide within 1 year of screening
Participants who have received treatment with immunoadsorption columns (such as Prosorba columns), mycophenolate mofetil (Cellcept®), cyclosporine A or other calcineurin inhibitors, or D-Penicillamine.
Clareo Health | Phase IIIB Subcutaneous Missed Dose Study
